Related Experiment Video

Updated: Sep 26, 2026

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial

Kathryn A Kohler1, Ali Jaffer M Suleiman, Susan E Robertson

  • 1Global Immunization Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kik9@cdc.gov

The Journal of Infectious Diseases
|May 2, 2003
PubMed

Insights

Measles and rubella vaccine immunogenicity was assessed in Omani children. High seroconversion rates were achieved with a single measles vaccine dose at 9 months and a measles-rubella vaccine dose at 15 months.

Area of Science:

  • Pediatrics
  • Immunology
  • Vaccinology

Background:

  • Measles and rubella are significant public health concerns globally.
  • Effective vaccination strategies are crucial for disease prevention in children.
  • Understanding vaccine immunogenicity in diverse populations is essential for public health policy.

Purpose of the Study:

  • To evaluate the immunogenicity of a measles vaccine administered at 9 months.
  • To assess the immunogenicity of a measles-rubella (MR) vaccine administered at 15 months.
  • To determine the impact of a two-dose measles vaccination schedule on seroconversion rates.

Main Methods:

  • A prospective immunogenicity trial involving 1025 infants in Oman.
  • Children received measles vaccine at 9 months and MR vaccine at 15 months.
  • Serum samples were collected and tested for measles-specific and rubella-specific IgG antibodies.

Main Results:

  • Measles vaccine at 9 months resulted in 98.1% seroconversion.
  • A second measles dose at 15 months boosted seroconversion to 99% in previously seronegative children.
  • Rubella vaccine at 15 months achieved 98.8% seroconversion by 16 months.

Conclusions:

  • A single dose of measles vaccine at 9 months is highly immunogenic.
  • The MR vaccine at 15 months effectively addressed the measles immunogenicity gap.
  • The vaccination schedule demonstrated high rubella seroconversion rates, indicating vaccine effectiveness.

More Related Videos

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.